About 50 results
Open links in new tab
  1. Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous ...

    Mar 11, 2026 · Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism. However, uncertainty remains about the difference in bleeding risk …

  2. The New England Journal of Medicine | Research & Review Articles on ...

    The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...

  3. Discontinuation of Beta-Blocker Therapy after Myocardial Infarction ...

    Mar 30, 2026 · The role of long-term beta-blocker therapy after a myocardial infarction in patients without left ventricular systolic dysfunction or heart failure is unclear in the era of contemporary …

  4. Romiplostim versus Placebo for Chemotherapy-Induced …

    Mar 11, 2026 · Chemotherapy-induced thrombocytopenia (CIT) is a common complication of chemotherapy that is associated with bleeding, reduced relative dose intensity, and potentially worse …

  5. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer

    Feb 18, 2026 · Patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy proceed directly to radical cystectomy with pelvic lymph-node dissection. …

  6. Recently Published | The New England Journal of Medicine

    3 days ago · Explore this issue of The New England Journal of Medicine (Vol. 0 No. 0).

  7. Teclistamab plus Daratumumab in Relapsed or Refractory Multiple …

    Dec 9, 2025 · In a phase 1–2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated …

  8. Medical Management and Revascularization for Asymptomatic Carotid ...

    Nov 21, 2025 · Improvements in medical therapy, carotid-artery stenting, and carotid endarterectomy call into question the preferred management of asymptomatic carotid stenosis. Whether adding …

  9. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for …

    Sep 16, 2025 · Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity.

  10. Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head …

    Jun 18, 2025 · The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma …